Spin Therapeutics is a biotechnology company focused on developing novel protein disaggregation therapies for the treatment of Parkinson's disease and other neurodegenerative disorders characterized by protein aggregation. The company's unique approach targets established protein aggregates directly, aiming to reverse or prevent the formation of toxic oligomers and fibrils.
- Headquarters: United States
- Founded: 2020
- Focus: Protein disaggregation small molecules
- Therapeutic Areas: Parkinson's Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis
Spin Therapeutics develops small molecule drugs that directly target and clear established protein aggregates:
- Oligomer breakers: Molecules that destabilize toxic oligomeric species
- Fibril disassemblers: Compounds that promote disassembly of mature fibrils
- Aggregate seeding inhibitors: Agents that prevent template-guided aggregation
The company's disaggregation approach works through:
- Direct aggregate targeting: Binding to existing aggregates rather than monomers
- Conformational remodeling: Changing aggregate structure to less toxic forms
- Enhanced clearance: Facilitating cellular degradation of disassembled proteins
- Template blocking: Preventing aggregates from seeding further aggregation
| Program |
Target |
Indication |
Development Status |
| ST-101 |
Alpha-synuclein |
Parkinson's Disease |
Preclinical |
| ST-201 |
Tau protein |
Alzheimer's Disease |
Discovery |
¶ ST-101 (Lead Candidate)
ST-101 is Spin Therapeutics' lead preclinical candidate:
- Mechanism: Small molecule that promotes disassembly of alpha-synuclein aggregates
- Target: Lewy bodies and Lewy neurites in Parkinson's disease
- Route: Oral delivery
- Status: IND-enabling studies
Spin Therapeutics' approach is based on emerging research demonstrating that:
- Protein aggregates in neurodegenerative diseases are dynamic structures
- Small molecules can directly interact with aggregates to promote clearance
- Disaggregation can be achieved without causing toxic intermediate release
¶ Competitive Landscape
Spin Therapeutics competes with other companies developing anti-aggregation approaches:
- Modag — Alpha-synuclein aggregation inhibitors
- Vanqua Bio — Alpha-synuclein aggregation inhibitors
- Prothena — Protein degradation platform
- Yumanity Therapeutics — Protein misfolding platform (acquired)
- Spin Therapeutics Company Website
- Literature on protein disaggregation in neurodegeneration